CYSTM1 is a potential diagnostic and prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
Collectively, our study established CYSTM1 as a dual-purpose biomarker for HCC diagnosis and prognosis, offering a therapeutic target for TLR pathway modulation. The immune-linked mechanism uncovered here addressed a critical gap in HCC personalized therapy.
Authors
- Xiangnan Kong (ORCID: https://orcid.org/0000-0002-7403-5869)
- Jing Zhen (ORCID: https://orcid.org/0000-0003-2666-0827)
- Ning Zhang (ORCID: https://orcid.org/0000-0002-6430-4236)
Institutions
- Qingdao University (CN)
- Shandong University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/jgo-2025-353
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00